Phaseline

Targets › CD44

CD44 (CD44 antigen): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Feb 2028.

Cell-surface receptor that plays a role in cell-cell interactions, cell adhesion and migration, helping them to sense and respond to changes in the tissue microenvironment. Participates thereby in a wide variety of cellular functions including the activation, recirculation and homing of T-lymphocytes, hematopoiesis, inflammation and response to bacterial infection. (UniProt, P16070)

Open in Phaseline: the race on CD44, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Tasly PharmaceuticalsP134 cells
CD44/CD133 dual-targeting CAR-T cells
CD44, CD133Phase 1Recurrent Glioblastoma IDH WildtypeFeb 2028

Conditions

Recurrent Glioblastoma IDH Wildtype (1)

Modalities

other (1)

Companies

Tasly Pharmaceuticals (1)

Related targets

CD133 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.